Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 20/20 | 0.79 |
| ▸ | INSR | P06213 | 7/20 | 0.79 |
| ▸ | LYN | P07948 | 5/20 | 0.79 |
| ▸ | LCK | P06239 | 4/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.79 |
| ▸ | FLT4 | P35916 | 4/20 | 0.79 |
| ▸ | KDR | P35968 | 4/20 | 0.79 |
| ▸ | FLT3 | P36888 | 4/20 | 0.79 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.79 |
| ▸ | SRC | P12931 | 3/20 | 0.79 |
| ▸ | KIT | P10721 | 3/20 | 0.79 |
| ▸ | FLT1 | P17948 | 3/20 | 0.79 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.79 |
| ▸ | CSF1R | P07333 | 3/20 | 0.79 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.79 |
| ▸ | MARK3 | P27448 | 3/20 | 0.79 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.79 |
| ▸ | BLK | P51451 | 3/20 | 0.79 |
| ▸ | NEK2 | P51955 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731416 | 1.00 | IGF1R (0.79) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL12232237 | 0.98 | IGF1R (0.79) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL1983470 | 0.88 | IGF1R (1.00) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL30631775 | 0.88 | IGF1R (1.00) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL95142 | 0.88 | IGF1R (1.00) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL1983472 | 0.88 | IGF1R (1.00) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL29356373 | 0.88 | IGF1R (1.00) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL1985751 | 0.88 | IGF1R (0.98) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL1985750 | 0.88 | IGF1R (0.98) | IGF1RINSRLYNLCKFGFR1 | |
| SCHEMBL1985344 | 0.88 | IGF1R (0.98) | IGF1RINSRLYNLCKFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | IGF1R 7/4885INSR 23/4885LYN 4343/4885 |
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | IGF1R 1/4885INSR 20/4885LYN 474/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | IGF1R 2978/4885INSR 4146/4885LYN 3295/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | IGF1R 1/4885INSR 21/4885LYN 2803/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | IGF1R 4709/4885INSR 4597/4885LYN 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.